<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483427</url>
  </required_header>
  <id_info>
    <org_study_id>1984</org_study_id>
    <nct_id>NCT04483427</nct_id>
  </id_info>
  <brief_title>Multimodal Postoperative Analgesia Following OSA Surgery</brief_title>
  <official_title>Multimodal Postoperative Analgesia Using Accufuser for Multilevel Surgery for Obstructive Sleep Apnea (OSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bahaa Mohammed Refaie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the clinical efficacy and adverse effects of multimodal analgesic regimen
      consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device
      (Accufuser) for postoperative analgesia following multilevel OSA surgeries
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out at zero time (time to shift to PACU) .</time_frame>
    <description>visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 6 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 12 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 18 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 24 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 30 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 36 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 42 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>Assessment will be carried out 48 hours postoperatively</time_frame>
    <description>Visual analog pain score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>Zero time ( time to shift to PACU)</time_frame>
    <description>Ramsey sedation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Ramsey sedation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>12 hours postoperatively</time_frame>
    <description>Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>18 hours postoperatively</time_frame>
    <description>Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>30 hours postoperatively</time_frame>
    <description>Ramsey Sedation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>36 hours postoperatively</time_frame>
    <description>Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>42 hours postoperatively</time_frame>
    <description>Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Ramsey Sedation Ramsey Sedation Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>Zero time ( time to shift to PACU)</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>12 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>18 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>30 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>36 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>42 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of adverse effects</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>hypoxia, nausea, vomiting, itching</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>OSA patients after multilevel surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Nalbuphine, ketorolac, accufuser</intervention_name>
    <description>multimodal analgesic regimen consisting of nalbuphine combined with ketorolac using IV continuous infusion silicon device (Accufuser)</description>
    <arm_group_label>OSA patients after multilevel surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physical status of American Society of Anesthesiologists (ASA) II

          -  age between 30 - 50 years

          -  OSA patients diagnosed by polysomnography and stop-bang questionnaire

          -  enrolled for multilevel OSA surgery

        Exclusion Criteria:

          -  history of allergy to the study drugs

          -  history of hepatic, cardiopulmonary or renal disease

          -  history of any chronic pain on medication

          -  history of substance abuse

          -  psychiatric disorder

          -  lack of patient cooperation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bahaa M Refaie, MD</last_name>
    <phone>0201026887257</phone>
    <email>bahaarefaay@med.sohag.edu.eg</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Bahaa Mohammed Refaie</investigator_full_name>
    <investigator_title>Lecturer of anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

